Current Research Studies

A Phase 3, Randomised, Rater-Blinded, Multi-Centre Study to Evaluate the Efficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease Subjects Aged 18 and Older with an Extension Phase of up to 60 Months


What is the goal of the study?

To learn more about this study, please email the study team member listed below.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: